ReviewInternational journal of cancer2026
Lipid Metabolic Reprogramming in Lung Cancer: Mechanisms and Therapeutic Targets in the Tumor Microenvironment.
Review in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lung cancer remains a leading cause of cancer-related deaths globally, with tumor progression and metastasis being heavily influenced by the dynamic interactions within the tumor microenvironment (TME). Lipid metabolic reprogramming, a recognized hallmark of cancer, plays a crucial role in these processes. However, a comprehensive understanding of how cancer cell-intrinsic lipid metabolism and its crosstalk with immune and stromal cells collectively drive tumor metastasis remains to be fully elucidated. This review synthesizes preclinical and clinical evidence to map the interconnected lipid metabolic networks spanning tumor, immune, and stromal compartments. It highlights how cancer cell-autonomous lipid metabolic reprogramming and its metabolic crosstalk with immune and stromal cells drive lung cancer progression and therapy resistance, thereby reshaping the TME into a pro-tumorigenic ecosystem. Furthermore, we provide an in-depth analysis of the potential of therapeutic strategies targeting these metabolic pathways, discussing both the opportunities for development and the challenges that lie ahead. By integrating the multifaceted roles of lipid metabolism in the lung TME, this review provides a novel perspective on tumor biology and aims to inspire future research directions for innovative combination therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.